Publications and Presentations
Publications
Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice.
Authors: Min Wu, Lina Jung, Adrian B. Coopers, Christina Fleet, Lihao Chen, Lyne Breault, Kimberly Clark, Zhuau Cai, Sylvie Vincent, Steve Bottega, Qiong Shen, Andrea Richardson, Marcus Bosenburg, Stephen P. Naber, Ronald A. DePinho, Charlotte Kuperwasser, and Murray O. Robinson
Proc Natl Acad Sci U S A. 2009, vol.106, 7022-27. Click here for article.
Human-in-mouse breast cancer model
Authors: Min Wu and Murray O. Robinson
Cell Cycle 2009, vol. 8, 2317-18. Click here for article.
Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development (Chapter 16)
Authors: Ronan C. O'Hagan, Min Wu, William M. Rideout III, Yinghui Zhou and Joerg Heyer
Cancer Drug Discovery and Development: The Oncogenomics Handbook
Edited by W. J. LaRochelle and R. A. Shimkets © Humana Press Inc., April 2005.
Essential role for oncogenic Ras in tumour maintenance.
Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA.
Nature. 1999 Jul 29; 400(6743): 468-72.
Presentations
Poster Presented by Dr. Pankaj Bhargava entitled, “Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of tivozanib (AV-951), a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC)” Press release issued on 5/29/09. Read more.
Poster Presentation by Yinghui Zhou entitled, "Mouse Models of Hepatocellular Carcinoma Exhibit Features VEGF-driven Angiogenesis." Press Release issued on 4/21/09. Read more.
Poster Presentation by Kristan Meetze entitled, "Preclinical Efficacy and Pharmacodynamics of SCH 900105 (AV-299), an anti-HGF Antibody." Press Release issued on 4/19/09. Read more.
Poster Presented by William Rideout entitled, "Knock-in of human HGF into the mouse genome maintains endogenous HGF regulation and supports the growth of HGF-dependent human cancer cell lines."
Poster Presented by Lorena Lerner entitled, "Fibroblast growth factor receptor-2 cancer models for biomarker discovery and therapeutic response prediction."
Poster Presented by Lorena Lerner entitled, "Generation of in vivo tumor models driven by PI3 kinase submit p110alpha and their use in the development of inhibitors to the pathway."
Poster Presented by Lorena Lerner entitled, "Generation of in vivo tumor models driven by Insulin-Like Growth Factor Receptor IGF1R and their use in the development of OSI-906, a selective IGF1R inhibitor."
Poster Presented by Joseph Growney entitled, "Population based in vivo models of tumor metastasis."
Oral Presentation by Dr. Pankaj Bhargava entitled, "Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC): Interim results of a Phase 2 randomized discontinuation trial.”
Poster Presentation by Dr. Joerg Heyer entitled, "Oncogene and tissue specific pathway activation in an HER2 dependent mouse mammary tumor model."
Poster Presentation by Dr. Yinghui Zhou entitled, "Switching oncogene dependence in lung tumors in vivo."
Poster Presentation by Dr. Lorena Lerner entitled, "Generation of in vivo tumor models driven by ERBB family of receptor tyrosine kinases and their use in cancer drug discovery."
Poster Presenation by Dr. Karuppiah Kannan entitled, "Predicting rapamycin response using pathway profile in a population of genetically engineered hHER2 driven breast tumor model."
Poster Presented by Dr. Karuppiah Kannan entitled, "Human cancer relevant genomic alterations in a population based genetically engineered murine model of human breast cancer."
Poster Presentation by Dr. Lorena Lerner entitled, "Directed Complementation of inducible tumor models: an approach to generate broad panels of tumors with defined genetic contexts."
Poster Presentation by Dr. Yinghui Zhou entitled, "A chimeric mouse model of ovarian cancer driven by inducible expression of PI3K catalytic subunit (p110alpha)."
Poster presentation by Dr. Ronan O'Hagan from AVEO Pharmaceuticals entitled, "In vivo Genetic Approaches to Identify Mechanisms of Resistance to Inhibition of the HER2 Receptor Tyrosine Kinase".
Poster presentation by Dr. Joerg Heyer from AVEO Pharmaceuticals entitled, "In-vivo Characterization of Major Pathways Implicated in Human Lung Cancer using Chimeric Lung Tumor Models".
Presentation by Dr. Murray Robinson from AVEO Pharmaceuticals entitled, “Efficient generation of spontaneous human breast cancers in mice using defined genetic elements”.